Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

CELU
Celularity Inc. Class A Common Stock
stock NASDAQ

At Close
Jul 6, 2026 3:59:43 PM EDT
0.7900USD+27.804%(+0.1723)947,056
0.6300Bid   0.8000Ask   0.1700Spread
Pre-market
0.00USD-100.000%(-0.62)0
After-hours
Jul 6, 2026 4:52:30 PM EDT
0.7100USD-10.354%(-0.0800)15,798
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
10:17AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 28, 2022   Benzinga
04:59AM EST  Oppenheimer Initiates Coverage On Celularity with Outperform Rating, Announces Price Target of $9   Benzinga
Jan 18, 2022
09:53AM EST  Celuarity shares were trading higher after the company announced the FDA has granted Fast Track Designation for its genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-101.   Benzinga
08:14AM EST  Celularity Receives Fast Track Designation From U.S. FDA For Its NK Cell Therapy CYNK-101 In Development For The First-Line Treatment Of Advanced HER2/neu Positive Gastric And Gastroesophageal Junction Cancers   Benzinga
08:00AM EST  CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need   GlobeNewswire Inc
Jan 6, 2022
11:53AM EST  Celularity Files For U.S. Patent Titled 'PLACENTAL DERIVED NATURAL KILLER CELLS FOR TREATMENT OF CORONAVIRUS INFECTIONS'   Benzinga
Dec 27, 2021
08:03AM EST  Celularity Receives Fast Track Designation From U.S. FDA For Its NK Cell Therapy CYNK-001 In Development For The Treatment Of AML   Benzinga
08:00AM EST  Celularity Receives Fast Track Designation from U.S. FDA for its   GlobeNewswire Inc
Dec 13, 2021
08:09AM EST  Celularity Presents Preclinical Data On Allogeneic Genetically Modified Natural Killer And Allogeneic CAR-NK Cell Therapy Programs At ASH 2021   Benzinga
08:00AM EST  Celularity Presents Preclinical Data on Allogeneic Genetically   GlobeNewswire Inc
Nov 29, 2021
08:04AM EST  Celularity Announces FDA Clearance Of Investigational New Drug Application For Natural Killer Cell Therapy CYNK-101 In First-line Advanced Her2/Neu Positive Gastric And Gastroesophageal Junction Cancer   Benzinga
08:00AM EST  CYNK-101 is an investigational genetically engineered natural killer (NK) cell therapy designed to synergize with antibody therapeutics   GlobeNewswire Inc
Nov 24, 2021
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 24, 2021   Benzinga
06:03AM EST  Morgan Stanley Initiates Coverage On Celularity with Equal-Weight Rating, Announces Price Target of $9   Benzinga
Nov 15, 2021
11:06AM EST  Celularity Presents Preclinical Data On Allogeneic Genetically-Modified Natural Killer Cells At The Society For Immunotherapy Of Cancer 36th Annual Meeting   Benzinga
09:29AM EST  Celularity Reports Q3 2021 Revenue $10.622M   Benzinga
08:00AM EST  Celularity Inc. (Nasdaq: CELU) (Celularity) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021.   GlobeNewswire Inc
Nov 12, 2021
04:05PM EST  Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.   GlobeNewswire Inc
Oct 19, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021   Benzinga
06:43AM EDT  Truist Securities Initiates Coverage On Celularity with Buy Rating, Announces Price Target of $12   Benzinga
Sep 22, 2021
06:38AM EDT  Cramer Weighs In On Joby Aviation, Pitney Bowes And More   Benzinga
Sep 20, 2021
08:15AM EDT  Celularity And Oncternal Therapeutics Enter Into Research Collaboration To Evaluate Targeted Placental-Derived Cellular Therapies   Benzinga
08:15AM EDT  Celularity And Oncternal Therapeutics Enter Research Collaboration To Evaluate Targeted Placental-Derived Cellular Therapies   Benzinga
08:00AM EDT  Celularity and Oncternal Therapeutics Enter into Research   GlobeNewswire Inc
08:00AM EDT  Oncternal Therapeutics and Celularity Enter into Research   GlobeNewswire Inc
Sep 15, 2021
08:00AM EDT  Celularity Appoints Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as   GlobeNewswire Inc
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 16, 2021
05:49PM EDT  Pingtan Marine Enterprise, Adamis Pharma, Celularity, Carver Bancorp File For Non-Timely 10-Q   Benzinga
05:15PM EDT  -- Secured funding of approximately $138 million through merger and private placement investment in public equity (PIPE) financing -- Expanded Phase 1 clinical trial to include difficult-to-treat patient population -- Established multiple strategic and commercial partnerships   GlobeNewswire Inc
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Jul 29, 2021
03:02PM EDT  Longeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS   Benzinga
Jul 21, 2021
04:33PM EDT  EXCLUSIVE: Celularity's CEO On 'One-Size-Fits-All' Product, Palantir Connection   Benzinga
Jul 20, 2021
12:59PM EDT  Celularity CEO, Dr. Robert Hariri, In Earlier Benzinga Interview: One Of The Great Opportunities Of The Future Will Be To Find Ways To Arrest Degenerative Diseases And Even Improve The Functionality Of Organ Tissue By Enhancing The Stem Cell's Renewals   Benzinga
12:49PM EDT  EXCLUSIVE: Celularity CEO, Dr. Robert Hariri Says: Cellular Biology Is 'Here To Stay', However The Future Is The Combination Of Engineered Cells With Stem Cells To Improve Response To Disease And Human Performance To Help Inhibit The Aging Process   Benzinga
12:46PM EDT  EXCLUSIVE: Celularity CEO, Dr. Robert Hariri Says: One Of The Great Opportunities Of The Future Will Be To Find Ways To Arrest Degenerative Diseases And Even Improve The Functionality Of Organ Tissue By Enhancing The Stem Cell's Renewals   Benzinga
12:45PM EDT  EXCLUSIVE: Celularity CEO, Dr. Robert Hariri Says: Palantir Technologies Sought Out The Opportunity To Work With Celularity And Help Enhance The Quality And Accuracy Of Cellular Donations   Benzinga
12:42PM EDT  EXCLUSIVE: Celularity CEO, Dr. Robert Hariri Says: Company Now Has A Reliable Source For A One-Size-Fits-All Product For Cellular Medicine   Benzinga
12:34PM EDT  EXCLUSIVE: Celularity CEO Dr. Robert Hariri Begins Interview On Benzinga's 'Power Hour' YouTube Show   Benzinga
10:48AM EDT  EXCLUSIVE: Former PepsiCo President And Apple CEO John Sculley Tells A Steve Jobs Story   Benzinga
Jul 19, 2021
12:44PM EDT  EXCLUSIVE: John Sculley Says He Is Excited About Innovation Celularity Is Working On, Related To Stem Cells, Says He Plans To Be Working With/In Co. For Years To Come   Benzinga
12:43PM EDT  EXCLUSIVE: John Sculley Discussing Innovation At Co. He Is On Board Of, Celularity   Benzinga
08:57AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Jul. 19, 2021: RCL, CELU, CMG, NRXP, RCAT   Benzinga
Jul 16, 2021
08:00AM EDT  Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol CELU on July 19, 2021   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC